Mirae Asset Global Investments Co. Ltd. Makes New $8.14 Million Investment in argenex SE $ARGX

Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of argenex SE (NASDAQ:ARGX) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 8,488 shares of the company’s stock, valued at approximately $8,139,000.

Other large investors also recently added to or reduced their stakes in the company. Janus Henderson Group PLC lifted its stake in argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares during the last quarter. Jennison Associates LLC grew its stake in shares of argenex by 3.4% during the first quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after buying an additional 7,707 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of argenex by 1.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after buying an additional 2,579 shares during the last quarter. First Trust Advisors LP increased its holdings in shares of argenex by 98.9% in the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock worth $78,279,000 after buying an additional 53,293 shares during the period. Finally, Eagle Health Investments LP increased its holdings in shares of argenex by 21.7% in the first quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock worth $55,744,000 after buying an additional 13,606 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Trading Up 3.3%

argenex stock opened at $930.95 on Thursday. The firm has a market cap of $58.54 billion, a P/E ratio of 32.48, a P/E/G ratio of 0.83 and a beta of 0.48. argenex SE has a 1-year low of $661.85 and a 1-year high of $1,072.75. The firm has a 50-day moving average of $936.34 and a 200-day moving average of $856.24.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $7.44 by $0.36. The company had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Research analysts forecast that argenex SE will post 28.63 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ARGX has been the subject of a number of recent research reports. Guggenheim lowered their target price on argenex from $1,185.00 to $1,120.00 and set a “buy” rating for the company in a research note on Friday, October 23rd. Wells Fargo & Company decreased their price target on argenex from $1,356.00 to $1,336.00 and set an “overweight” rating on the stock in a research note on Friday, October 23rd. Barclays reiterated a “buy” rating on shares of argenex in a research report on Monday, September 7th. HC Wainwright increased their price objective on argenex from $940.00 to $1,202.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Finally, The Goldman Sachs Group restated a “buy” rating on shares of argenex in a report on Friday, September 25th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,158.76.

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.